Back to Feed
ClinicalTrials.gov|Clinical Trial
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Mesoblast, Inc.
Abstract
To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies. Phase: PHASE3 Status: COMPLETED Conditions: Crohn's Disease Interventions: Prochymal®
Keywords
Crohn's Disease